Satisfaction and experiences of patients taking fingolimod and involved in a pharmacy-based patient support program in Switzerland - a qualitative study.
Adult
Attitude of Health Personnel
Female
Fingolimod Hydrochloride
/ therapeutic use
Humans
Male
Medication Adherence
Middle Aged
Patient Safety
Patient Satisfaction
/ statistics & numerical data
Patients
/ psychology
Pharmaceutical Services
/ organization & administration
Pharmacists
/ psychology
Program Evaluation
Qualitative Research
Switzerland
Fingolimod
Multiple sclerosis
Patient perceptions
Patient satisfaction
Patient support program
Qualitative research
Specialty pharmacy service
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
14 May 2020
14 May 2020
Historique:
received:
29
10
2019
accepted:
30
04
2020
entrez:
16
5
2020
pubmed:
16
5
2020
medline:
1
12
2020
Statut:
epublish
Résumé
Fingolimod is an oral multiple sclerosis drug that is considered a specialty drug due to its high cost and safety issues. The Fingolimod Patient Support Program (F-PSP) is a specialty pharmacy service developed to ensure the responsible use of fingolimod by promoting patient safety and medication adherence. This study aims to explore the satisfaction, experiences and perceptions regarding the F-PSP among patients currently involved in this program or recently withdrawn. A qualitative study was conducted via individual, face-to-face semistructured interviews with patients involved in the F-PSP. The interviews were audio-recorded, transcribed verbatim, coded and analyzed via thematic content analysis. The main themes identified from the interviews (n = 17) were overall perception of the F-PSP, perception of the pharmacist-led consultations, perception of the tools (electronic monitor and drug intake graph), reasons to participate or potentially withdraw, and suggestions for improvements. Participants perceived the F-PSP as a reassuring support that complemented their medical care, providing a more human, personalized and person-centered approach than usual pharmacy care. Pharmacist-led consultations were valued for the medication-related and holistic support they provided. The importance of the pharmacist's attitude was emphasized. The electronic monitor was valued for promoting daily medication adherence and allowing the involvement of relatives, which reassured participants and their relatives. The participants appreciated the drug intake graph because it provided an objective overview of medication adherence, thereby reassuring, rewarding, and motivating them. The main reason to join the program was to be supported, especially with respect to medication adherence. Participants were satisfied with the F-PSP, each for different reasons. Their feedback enabled the identification of measures for the optimization of the F-PSP and should facilitate its dissemination and transfer to other drugs/diseases/populations. Essential elements of generic pharmacist-led patient support programs considered valuable from the patients' perspective were identified.
Sections du résumé
BACKGROUND
BACKGROUND
Fingolimod is an oral multiple sclerosis drug that is considered a specialty drug due to its high cost and safety issues. The Fingolimod Patient Support Program (F-PSP) is a specialty pharmacy service developed to ensure the responsible use of fingolimod by promoting patient safety and medication adherence. This study aims to explore the satisfaction, experiences and perceptions regarding the F-PSP among patients currently involved in this program or recently withdrawn.
METHODS
METHODS
A qualitative study was conducted via individual, face-to-face semistructured interviews with patients involved in the F-PSP. The interviews were audio-recorded, transcribed verbatim, coded and analyzed via thematic content analysis.
RESULTS
RESULTS
The main themes identified from the interviews (n = 17) were overall perception of the F-PSP, perception of the pharmacist-led consultations, perception of the tools (electronic monitor and drug intake graph), reasons to participate or potentially withdraw, and suggestions for improvements. Participants perceived the F-PSP as a reassuring support that complemented their medical care, providing a more human, personalized and person-centered approach than usual pharmacy care. Pharmacist-led consultations were valued for the medication-related and holistic support they provided. The importance of the pharmacist's attitude was emphasized. The electronic monitor was valued for promoting daily medication adherence and allowing the involvement of relatives, which reassured participants and their relatives. The participants appreciated the drug intake graph because it provided an objective overview of medication adherence, thereby reassuring, rewarding, and motivating them. The main reason to join the program was to be supported, especially with respect to medication adherence.
CONCLUSIONS
CONCLUSIONS
Participants were satisfied with the F-PSP, each for different reasons. Their feedback enabled the identification of measures for the optimization of the F-PSP and should facilitate its dissemination and transfer to other drugs/diseases/populations. Essential elements of generic pharmacist-led patient support programs considered valuable from the patients' perspective were identified.
Identifiants
pubmed: 32410681
doi: 10.1186/s12913-020-05278-3
pii: 10.1186/s12913-020-05278-3
pmc: PMC7227186
doi:
Substances chimiques
Fingolimod Hydrochloride
G926EC510T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
425Références
Drugs. 2013 May;73(6):545-62
pubmed: 23588595
J Am Pharm Assoc (Wash). 1999 Nov-Dec;39(6):835-42; quiz 882-4
pubmed: 10609450
J Clin Nurs. 2014 Jan;23(1-2):132-44
pubmed: 23451899
Prev Med. 2017 Jun;99:269-276
pubmed: 28315760
AIDS. 2007 Jan 30;21(3):271-81
pubmed: 17255734
Res Nurs Health. 2000 Aug;23(4):334-40
pubmed: 10940958
Patient Educ Couns. 2006 May;61(2):299-306
pubmed: 15970422
Int J Epidemiol. 2017 Apr 1;46(2):589-602
pubmed: 27864410
Value Health. 2013 Jul-Aug;16(5):863-71
pubmed: 23947982
Health Psychol. 2006 Jul;25(4):462-73
pubmed: 16846321
Adv Ther. 2011 Jan;28(1):51-61
pubmed: 21153000
Res Social Adm Pharm. 2017 Sep - Oct;13(5):959-968
pubmed: 28645553
Pharm World Sci. 2009 Oct;31(5):525-537
pubmed: 19588267
Br J Gen Pract. 2012 Apr;62(597):e233-42
pubmed: 22520910
AIDS Patient Care STDS. 2012 Jan;26(1):20-8
pubmed: 22149903
Health Res Policy Syst. 2019 Mar 7;17(1):27
pubmed: 30845968
Rheumatology (Oxford). 2015 Oct;54(10):1780-91
pubmed: 25972390
Arch Intern Med. 2007 Mar 26;167(6):540-50
pubmed: 17389285
J Gen Intern Med. 2016 Aug;31(8):929-40
pubmed: 27160414
BMC Public Health. 2012 Aug 14;12:652
pubmed: 22891794
Am J Health Syst Pharm. 2019 Jul 18;76(15):1150-1157
pubmed: 31201774
Maturitas. 2017 Nov;105:58-63
pubmed: 28705438
J Manag Care Spec Pharm. 2018 Apr;24(4):317-326
pubmed: 29578855
JAMA. 2013 Dec 25;310(24):2611-2
pubmed: 24264605
Front Pharmacol. 2013 Jul 25;4:91
pubmed: 23898295
J Asthma. 2010 Dec;47(10):1085-93
pubmed: 21039206
Eur J Cancer Care (Engl). 2017 Mar;26(2):
pubmed: 26059246
Can Fam Physician. 2017 Dec;63(12):e536-e542
pubmed: 29237650
Res Social Adm Pharm. 2012 May-Jun;8(3):206-16
pubmed: 21824822
J Neurosci Nurs. 2010 Oct;42(5 Suppl):S10-8
pubmed: 21049829
Pan Afr Med J. 2018 Jan 29;29:82
pubmed: 29875963
Clin Drug Investig. 2010;30(2):89-100
pubmed: 20067327
J Gen Intern Med. 2004 Nov;19(11):1096-103
pubmed: 15566438
Cancer Nurs. 2016 Mar-Apr;39(2):153-62
pubmed: 25815430
J Health Popul Nutr. 2017 Apr 13;36(1):11
pubmed: 28407794
Qual Quant. 2018;52(4):1893-1907
pubmed: 29937585
Res Social Adm Pharm. 2010 Jun;6(2):143-54
pubmed: 20511113
Ann Pharmacother. 2007 Dec;41(12):1962-70
pubmed: 17971403